AR115730A1 - Modificación de moléculas de unión para minimizar interacciones pre-existentes - Google Patents

Modificación de moléculas de unión para minimizar interacciones pre-existentes

Info

Publication number
AR115730A1
AR115730A1 ARP190101943A ARP190101943A AR115730A1 AR 115730 A1 AR115730 A1 AR 115730A1 AR P190101943 A ARP190101943 A AR P190101943A AR P190101943 A ARP190101943 A AR P190101943A AR 115730 A1 AR115730 A1 AR 115730A1
Authority
AR
Argentina
Prior art keywords
binding molecules
modification
minimize
minimize pre
interactions
Prior art date
Application number
ARP190101943A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR115730A1 publication Critical patent/AR115730A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación está dirigida a la modificación de moléculas de unión para minimizar las interacciones de unión preexistentes, inclusive moléculas de unión modificadas genéticamente para minimizar o mitigar la reactividad inespecífica en la matriz de una muestra provocada por interacciones de unión no específicas de un fármaco.
ARP190101943A 2018-07-10 2019-07-10 Modificación de moléculas de unión para minimizar interacciones pre-existentes AR115730A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862695988P 2018-07-10 2018-07-10

Publications (1)

Publication Number Publication Date
AR115730A1 true AR115730A1 (es) 2021-02-17

Family

ID=67544330

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101943A AR115730A1 (es) 2018-07-10 2019-07-10 Modificación de moléculas de unión para minimizar interacciones pre-existentes

Country Status (15)

Country Link
US (2) US11448651B2 (es)
EP (1) EP3820891A1 (es)
JP (1) JP2021531245A (es)
KR (1) KR20210030378A (es)
CN (1) CN112543768B (es)
AR (1) AR115730A1 (es)
AU (1) AU2019302642A1 (es)
BR (1) BR112020026784A2 (es)
CA (1) CA3104873A1 (es)
EA (1) EA202190228A1 (es)
IL (1) IL279803A (es)
MX (1) MX2021000239A (es)
SG (1) SG11202012835RA (es)
TW (2) TW202428612A (es)
WO (1) WO2020014358A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR115730A1 (es) 2018-07-10 2021-02-17 Regeneron Pharma Modificación de moléculas de unión para minimizar interacciones pre-existentes

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1822857A (zh) * 2003-06-02 2006-08-23 阿莱克申药物公司 去免疫原性抗cd3抗体
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
TW200808347A (en) 2006-03-23 2008-02-16 Kirin Brewery Agonistic antibody directed against human thrombopoietin receptor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2240769A1 (en) 2008-01-15 2010-10-20 Stichting Sanquin Bloedvoorziening Method and kits for detecting antibodies against therapeutic antibodies
CA2740098A1 (en) 2008-10-10 2010-04-15 Valerie Odegard Tcr complex immunotherapeutics
CA2741114A1 (en) 2008-10-24 2010-04-29 Cornelis Lammert Verweij Biomarkers for predicting the development of chronic autoimmune diseases
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
WO2010122148A1 (en) 2009-04-24 2010-10-28 Boehringer Ingelheim International Gmbh An improved antibody domain and antibody fragments and antibodies based thereon
US8586713B2 (en) * 2009-06-26 2013-11-19 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
WO2011074965A1 (en) 2009-12-17 2011-06-23 Stichting Sanquin Bloedvoorziening Methods and means for counteracting an activity of an fc domain
JP2014518632A (ja) 2011-06-01 2014-08-07 モアハウス スクール オブ メディスン ケモカイン−免疫グロブリン融合ポリペプチド、組成物、その作製および使用の方法
EP2987806A3 (en) * 2011-08-17 2016-07-13 Glaxo Group Limited Modified single variable domain antibodies with reduced binding to anti-drug-antibodies
BR112015021462A2 (pt) 2013-03-06 2017-10-10 Adimab Llc anticorpos biespecíficos anti-c-met tandem fc
TWI633891B (zh) * 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
KR102100419B1 (ko) 2013-09-13 2020-04-14 베이진 스위찰랜드 게엠베하 항-pd1 항체 및 이의 치료 및 진단 용도
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by adding an IL-4R antagonist
WO2015187596A2 (en) * 2014-06-02 2015-12-10 Regeneron Pharmaceuticals, Inc. Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
KR20170080590A (ko) * 2014-11-05 2017-07-10 에프. 호프만-라 로슈 아게 효과기 기능 억제된 인간 또는 인간화된 약물 항체에 대항하는 항-약물 항체의 확인 방법
KR20170081262A (ko) * 2014-11-14 2017-07-11 사노피 바이오테크놀로지 Ｉｌ-4ｒ 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
AU2016344665C1 (en) * 2015-10-29 2023-07-27 F. Hoffmann-La Roche Ag Anti-variant Fc-region antibodies and methods of use
EA201990747A1 (ru) * 2016-09-19 2019-10-31 Способы лечения иммунных нарушений с применением белков, связывающих pd–1
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
US11866512B2 (en) 2017-11-22 2024-01-09 Vacara Ab Antibodies to citrullinated proteins
AR115730A1 (es) 2018-07-10 2021-02-17 Regeneron Pharma Modificación de moléculas de unión para minimizar interacciones pre-existentes
EP3980781A1 (en) 2019-06-07 2022-04-13 Sanquin Innovatie B.V. Methods and compounds for typing rheumatoid factors

Also Published As

Publication number Publication date
EP3820891A1 (en) 2021-05-19
WO2020014358A1 (en) 2020-01-16
BR112020026784A2 (pt) 2021-03-30
CA3104873A1 (en) 2020-01-16
KR20210030378A (ko) 2021-03-17
EA202190228A1 (ru) 2021-04-14
MX2021000239A (es) 2021-03-25
US20230266333A1 (en) 2023-08-24
US20200018754A1 (en) 2020-01-16
TWI838388B (zh) 2024-04-11
AU2019302642A1 (en) 2021-02-25
CN112543768A (zh) 2021-03-23
TW202021984A (zh) 2020-06-16
IL279803A (en) 2021-03-01
SG11202012835RA (en) 2021-01-28
TW202428612A (zh) 2024-07-16
US11448651B2 (en) 2022-09-20
JP2021531245A (ja) 2021-11-18
CN112543768B (zh) 2024-05-03

Similar Documents

Publication Publication Date Title
CY1124384T1 (el) Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3
CL2017000954A1 (es) Moléculas de unión a antígeno biespecificas activadoras de células t
CO2017013710A2 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t.
CL2021001603A1 (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
CO2018000710A2 (es) Anticuerpos biespecíficos específicos para un receptor de tnf coestimulador
CY1126145T1 (el) Κατασκευασματα αντισωματων για flt3 και cd3
CY1123441T1 (el) Μορια με ειδικοτητα στα cd45 και cd79
CL2023000907A1 (es) Anticuerpos de unión a gprc5d
CR20170032A (es) Moleculas biespecíficas de unión a antígeno activadoras de células t
CY1123005T1 (el) Κατασκευασματα αντισωματος για cdh19 και cd3
CL2021001506A1 (es) Anticuerpos que se unen a cd3
AR109771A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
CO2019009432A2 (es) Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap.
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
CO6551674A2 (es) Anticuerpos anti-her3 y usos de los mismo
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
BRPI0821777B8 (pt) anticorpo biespecífico bivalente, método para a preparação do mesmo e composição
AR094896A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
BR112016023046A8 (pt) kit compreendendo anticorpos e agentes redutores
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
BR112018075644A2 (pt) anticorpos anti-cd98 e conjugados de anticorpo e fármaco
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
ECSP14013220A (es) Moléculas biespecíficas de unión a antígeno activadoras de células t